Item 7.01. Regulation FD Disclosure.

On February 22, 2022, BioCryst Pharmaceuticals, Inc. (the "Company") issued a press release announcing the enrollment of the first patient in the RENEW proof-of-concept basket study with its oral Factor D inhibitor, BCX9930, in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN), and primary membranous nephropathy (PMN). A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits

Exhibit No.       Description

                    Press release dated February 22, 2022 entitled "BioCryst
  99.1            Begins Patient Enrollment in RENEW Proof-of-Concept Trial
                  Evaluating BCX9930 for Patients with Renal Complement-mediated
                  Diseases"
104               Cover Page Interactive Data File (embedded within the Inline
                  XBRL document)

© Edgar Online, source Glimpses